This narrative review examines the cross-talk between secretomes from mesenchymal stem cells (MSCs) and retinal cells (RPE, Müller glia) in the context of retinal disease therapy.
World Journal of Stem Cells · 8 authors, 13 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review examines the cross-talk between secretomes from mesenchymal stem cells (MSCs) and retinal cells (RPE, Müller glia) in the context of retinal disease therapy.
This is a narrative review summarizing preclinical evidence on the paracrine cross-talk between mesenchymal stem cell (MSC) and retinal cell secretomes. Conversely, retinal cell secretomes can influence MSC phenotype. The central implication is that understanding and manipulating this cross-talk could lead to novel, cell-free therapies for retinal diseases. The review highlights key factors like FGF, CXCL12, and miRNAs but notes major challenges remain, including specific characterization of factors, improved ocular delivery methods, and developing personalized therapeutic combinations.